期刊文献+

三联疗法联合麦滋林-S颗粒对幽门螺杆菌阳性患者胃溃疡的疗效 被引量:11

Efficacy of marzulene-S combined with triple therapy in treating Hp-positive patients with gastric ulcer
原文传递
导出
摘要 目的观察三联疗法联合麦滋林-S颗粒治疗成人活动期胃溃疡的效果。方法 164例幽门螺杆菌(Hp)检测阳性并经胃镜证实的胃溃疡患者随机分为两组:对照组80例应用奥美拉唑20mg+阿莫西林1000mg+克拉霉素500mg,2次/d三联治疗7d后,继续单用奥美拉唑20mg,1次/d,连服8周;治疗组84例在对照组基础上加服麦滋林-S颗粒0.67g,3次/d,共9周。治疗前后行胃镜检查和Hp检测,记录治疗前后溃疡愈合、Hp感染及治疗后半年溃疡复发情况。结果治疗组临床显效率78.6%,高于对照组的56.3%(P<0.05)。治疗结束后6个月随访,治疗组复发率3.6%,低于对照组的12.5%(P<0.05)。结论三联疗法联合麦滋林-S颗粒对Hp阳性患者胃溃疡的疗效较好,并能减少复发率。 Objective To explore the efficacy of marzulene-S combined with triple therapy (omeprazole 20 nag+amoxyicillin 1.0 g+clarithromycin 500 rag, bid for 7 days and followed by omeprazole 20 nag daily for 8 weeks) in treating Helicobacter pylori(Hp)-positive patients with active gastric ulcer. Methods A total of 164 Hp-positive cases with active gastric ulcer confirmed by gastroscopy was randomly treated with triple therapy plus marzulene-S 0. 67 g, tid for 9 weeks (group A,84 cases) or triple therapy(group B, 80 cases). The therapeutic efficacy was evaluated by gastroscopy and examination for Hp before and after treatment. Results The excellence rate was higher in group A than that in group B (78. 6% vs. 56. 3%) (P〈0. 05). The recurrence rate was lower in group A than that in group B (3.6% vs. 12.5%. ) (P〈0. 05). Conclusion Marzulene-S combined with triple therapy is reliable and effective in treating gastric ulcer patients with Hp-positive patients with active gastric ulcer with less recurrence rate.
出处 《江苏医药》 CAS 北大核心 2013年第11期1269-1270,共2页 Jiangsu Medical Journal
关键词 麦滋林-S颗粒 幽门螺杆菌 胃溃疡 Marzulene-S Helicobacter pylori Gastric ulcer
  • 相关文献

参考文献3

二级参考文献12

  • 1姚希贤.消化性溃疡治疗的进展[J].中华内科杂志,1995,34(3):208-210. 被引量:37
  • 2Rossella Cianci,Massimo Montalto,Franco Pandolfi,Giovan Battista Gasbarrini,Giovanni Cammarota.Third-line rescue therapy for Helicobacter pylori infection[J].World Journal of Gastroenterology,2006,12(15):2313-2319. 被引量:31
  • 3夏扬潮,姜海行,覃山羽,黄振宁.埃索美拉唑短程三联疗法对幽门螺杆菌阳性十二指肠溃疡的疗效[J].临床荟萃,2007,22(4):268-270. 被引量:40
  • 4Naohito Shirai,Mitsushige Sugimoto,Chise Kodaira,Masafumi Nishino,Mutsuhiro Ikuma,Masayoshi Kajimura,Kyoichi Ohashi,Takashi Ishizaki,Akira Hishida,Takahisa Furuta. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy[J] 2007,European Journal of Clinical Pharmacology(8):743~749
  • 5Jacob Yahav,Zmira Samra,Yaron Niv,Charlesnika T. Evans,Douglas J. Passaro,Gabriel Dinari,Haim Shmuely. Susceptibility-Guided vs. Empiric Retreatment of Helicobacter pylori Infection After Treatment Failure[J] 2006,Digestive Diseases and Sciences(12):2316~2321
  • 6Akihito Nagahara,Hiroto Miwa,Masato Kawabe,Akihiko Kurosawa,Daisuke Asaoka,Mariko Hojo,Katsuyori Iijima,Takeshi Terai,Toshifumi Ohkusa,Akihisa Miyazaki,Nobuhiro Sato. Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen[J] 2004,Journal of Gastroenterology(11):1051~1055
  • 7Tadashi Shimoyama,Shinsaku Fukuda,Tatsuya Mikami,Michio Fukushi,Akihiro Munakata. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population[J] 2004,Journal of Gastroenterology(10):927~930
  • 8Maria Pina Dore,Gioacchino Leandro,Giuseppe Realdi,Antonia Rogado Sepulveda,David Yates Graham. Effect of Pretreatment Antibiotic Resistance to Metronidazole and Clarithromycin on Outcome of Helicobacter pylori Therapy[J] 2000,Digestive Diseases and Sciences(1):68~76
  • 9王吉耀.内科学[M]北京:人民卫生出版社,2005419-428.
  • 10叶任高;陆再英.内科学[M]北京:人民卫生出版社,2003384.

共引文献28

同被引文献69

引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部